Glaxo Eyes Court Ruling On Seritide Patent

Law360 (March 11, 2004, 12:00 AM EST) -- A U.K. court is expected to decide later this month on the validity of a key patent on GlaxoSmithKline’s asthma drug Seritide.

Indian generic drugmaker Cipla has challenged a key U.K. patent on the drug, which expires in 2013, on the grounds of obviousness.

Cipla, along with Neolab — its distributor in the U.K. —filed a case in a London court in the first quarter of 2003, seeking revocation of one of the patents on Seretide, a combination of asthma drugs fluticasone and salmeterol.

GlaxoSmithKline also...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.